Recombinant Human CEACAM-6/CD66c Fc Avi-tag Protein, CF

Recombinant Human CEACAM-6/CD66c Fc Avi-tag Protein, CF Summary

Product Specifications

Product Datasheets

Carrier Free

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Background: CEACAM-6/CD66c

Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM-6), previously called nonspecific cross-reacting antigen (NCA) or CD66c, is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily primarily found in mammals. CEACAMs are transmembrane proteins used by several bacterial pathogens to bind and invade host cells (1-3). Mature, human CEACAM-6 is a GPI-linked membrane protein that contains an extracellular domain (ECD) with one N-terminal V-type Ig-like domain and two C2-type Ig-like domains (1, 3). The GPI membrane anchor is attached at the C-terminus following cleavage of the propeptide (4). The mature ECD of human CEACAM-6 shares 46% amino acid sequence identity to rat CEACAM-6 and is absent in mouse. CEACAM-6 is an intercellular adhesion molecule and forms both homotypic and heterotypic bonds with CEACAM-1, -5 and -8 through interaction of the V-type Ig-like domains (5, 6). CEACAM-6 is expressed by granulocytes and their precursors and granulocyte activation enhances surface expression by mobilizing CEACAM-6 from storage in azurophilic granules (7). CEACAM-6 is also expressed in epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas and hyperplastic polyps (7, 8). CEACAM-6 often shows aberrant expression in acute lymphocytic leukemias, and over-expression confers resistance to adhesion-related apoptosis (anoikis) in tumor cells (9‑11). CEACAM-6 expression is elevated in many solid tumors including breast, pancreatic, colonic and non-small-cell lung carcinoma, and is a biomarker or potential therapeutic for other carcinomas (12, 13). CEACAM-6 has been identified as the glycoprotein receptor for influenza virus and plays a role in virus entry (14). Our Avi-tag Biotinylated CEACAM-6 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

Related Research Areas

• Adhesion Molecules in Angiogenesis
• Cancer Biomarkers
• Cancer Stem Cell Markers
• Epithelial Cell Markers and Intracellular Molecules
• Granulocyte Markers
• Immunoglobulin Superfamily CAMs
• Myeloid Lineage Markers
• Search Immune Checkpoint Targets
• Surface Ectodermal Cells